Johnson & Johnson to Face New Lawsuits from Risperdal Mass Tort Cases
Johnson & Johnson in conjunction with its subsidiary, Janssen Pharmaceuticals will soon be facing lawsuits demanding punitive damages following complaints of gynecomastia or male breast growth allegedly caused by Risperdal. The pharmaceutical is an antipsychotic drug used for treating schizophrenia in adults. A three-judge panel in the Pennsylvania Superior Court ruled in favor of thousands of plaintiffs belonging to the Philadelphia Mass Tort Docket. These plaintiffs are hoping to receive compensation after experiencing adverse side effects following the usage of Risperdal.
The defendants are facing allegations of failing to adequately warn the medical community and its patients about possible links between Risperdal and gynecomastia. Enlarged breasts in men typically are caused by a hormone imbalance. The dangerous drugs cases are joined by two coordinated actions filed in Los Angeles and Philadelphia. Trials have been scheduled in the coming months with court dates set for December 3, 2018, January 22, 2019, and February 4, 2019.
At least 13,000 product liability claims regarding Risperdal have been filed in courts across the nation. In February 2015, a 20-year-old man received a $2.5 million damage award in the first Risperdal trial successfully brought to court involving gynecomastia. Currently, there are approximately 2,000 pending Risperdal mass tort cases in the Philadelphia Court of Common Pleas. Risperdal has also been linked to other serious alleged injuries, such as vomiting, skin rash, and anxiety.
In any product liability or dangerous drugs case, it can be difficult to make sense of what facts matter and how to best build a case to receive the damages you deserve. With such a high number of Risperdal mass tort cases, you or a loved one might find yourself in need of an experienced Risperdal mass tort cases lawyer. To speak with a dedicated dangerous drugs attorney that will fight for your rights, please contact us here.